Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome.

Tock L, Carneiro G, Pereira AZ, Tufik S, Zanella MT.

Int J Endocrinol. 2014;2014:620605. doi: 10.1155/2014/620605. Epub 2014 May 7.

PMID:
24895496
[PubMed]
Free PMC Article
2.

Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.

Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE.

J Clin Endocrinol Metab. 2003 Oct;88(10):4682-8.

PMID:
14557441
[PubMed - indexed for MEDLINE]
3.

Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.

Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS.

J Clin Endocrinol Metab. 1996 Aug;81(8):2854-64.

PMID:
8768842
[PubMed - indexed for MEDLINE]
4.

Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.

Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P.

Metabolism. 1999 Apr;48(4):437-41.

PMID:
10206434
[PubMed - indexed for MEDLINE]
5.

Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.

Tsilchorozidou T, Honour JW, Conway GS.

J Clin Endocrinol Metab. 2003 Dec;88(12):5907-13.

PMID:
14671189
[PubMed - indexed for MEDLINE]
6.

[Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].

Li X, Lin JF.

Zhonghua Yi Xue Za Zhi. 2005 Dec 7;85(46):3266-71. Chinese.

PMID:
16409817
[PubMed - indexed for MEDLINE]
7.

Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.

Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM.

J Clin Endocrinol Metab. 2009 Sep;94(9):3558-66. doi: 10.1210/jc.2009-0837. Epub 2009 Jun 30.

PMID:
19567518
[PubMed - indexed for MEDLINE]
8.

Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.

Yildiz BO, Yarali H, Oguz H, Bayraktar M.

J Clin Endocrinol Metab. 2003 May;88(5):2031-6.

PMID:
12727950
[PubMed - indexed for MEDLINE]
9.

Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome.

Grulet H, Hecart AC, Delemer B, Gross A, Sulmont V, Leutenegger M, Caron J.

Clin Endocrinol (Oxf). 1993 Jun;38(6):621-6.

PMID:
8334748
[PubMed - indexed for MEDLINE]
10.

Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.

Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.

J Clin Endocrinol Metab. 2007 Jun;92(6):2066-73. Epub 2007 Mar 13.

PMID:
17356050
[PubMed - indexed for MEDLINE]
11.

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.

Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I.

J Clin Endocrinol Metab. 2001 Oct;86(10):4666-73.

PMID:
11600523
[PubMed - indexed for MEDLINE]
12.

[The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].

Liang X, Zhuang G, Fan Q.

Zhonghua Yi Xue Za Zhi. 1997 Apr;77(4):266-9. Chinese.

PMID:
9596926
[PubMed - indexed for MEDLINE]
13.

The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.

Holte J, Bergh T, Gennarelli G, Wide L.

Clin Endocrinol (Oxf). 1994 Oct;41(4):473-81.

PMID:
7955458
[PubMed - indexed for MEDLINE]
14.

24-hour serum cortisol profiles in women with polycystic ovary syndrome.

Prelević GM, Würzburger MI, Balint-Perić L.

Gynecol Endocrinol. 1993 Sep;7(3):179-84.

PMID:
8291455
[PubMed - indexed for MEDLINE]
15.
16.

Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.

Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR.

J Clin Endocrinol Metab. 1999 Mar;84(3):946-50.

PMID:
10084576
[PubMed - indexed for MEDLINE]
17.

Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.

Dale PO, Tanbo T, Vaaler S, Abyholm T.

Fertil Steril. 1992 Sep;58(3):487-91.

PMID:
1521640
[PubMed - indexed for MEDLINE]
18.

Sonographic parameters and hormonal status in lean and obese women with polycystic ovary syndrome.

Sengos C, Andreakos C, Iatrakis G.

Clin Exp Obstet Gynecol. 2000;27(1):35-8.

PMID:
10758797
[PubMed - indexed for MEDLINE]
19.

The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.

Dunaif A, Mandeli J, Fluhr H, Dobrjansky A.

J Clin Endocrinol Metab. 1988 Jan;66(1):131-9.

PMID:
2961783
[PubMed - indexed for MEDLINE]
20.

Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.

Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N.

Hum Reprod. 2008 Jul;23(7):1602-6. doi: 10.1093/humrep/den109. Epub 2008 Mar 31.

PMID:
18378560
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk